CP690,550 — Competitive Intelligence Brief

CP690,550 (CP690,550) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK inhibitor. Area: Immunology.

phase 3 JAK inhibitor JAK1, JAK3 Immunology Small molecule

Target snapshot

CP690,550 (CP690,550) — Pfizer. CP690,550 is a JAK inhibitor that selectively blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CP690,550 TARGET	CP690,550	Pfizer	phase 3	JAK inhibitor	JAK1, JAK3
Tofacitinib tablet	Tofacitinib tablet	Shanghai Zhongshan Hospital	marketed	JAK inhibitor	JAK1, JAK3
Tofacitinib with methotrexate	Tofacitinib with methotrexate	Pfizer	marketed	JAK inhibitor + DMARD	JAK1, JAK3 (tofacitinib); dihydrofolate reductase (methotrexate)
CP-690,550	CP-690,550	Pfizer	marketed	JAK inhibitor	JAK1, JAK3
CP-690,550 (tofacitinib)	CP-690,550 (tofacitinib)	Pfizer	phase 3	JAK inhibitor	JAK1, JAK3, JAK2
Placebo/CP-690,550	Placebo/CP-690,550	Pfizer	phase 3	JAK inhibitor	JAK1, JAK3
Pf-07293893	pf-07293893	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) pathway	Not available

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK inhibitor class)

1. Pfizer · 19 drugs in this class
2. Aclaris Therapeutics, Inc. · 2 drugs in this class
3. Beijing Friendship Hospital · 2 drugs in this class
4. Azienda Ospedaliero, Universitaria Pisana · 1 drug in this class
5. CAGE Bio Inc. · 1 drug in this class
6. CTI BioPharma · 1 drug in this class
7. Celgene · 1 drug in this class
8. Fred Hutchinson Cancer Center · 1 drug in this class
9. LEO Pharma · 1 drug in this class
10. McMaster University · 1 drug in this class